Galatea Bio has launched StrataRisk™, a SaaS platform leveraging AI-powered polygenic risk scores (PRS) to enhance common disease risk assessment. StrataRisk™ addresses limitations in traditional genetic testing, which primarily identifies rare, high-penetrance mutations, by incorporating polygenic risk into the analysis. It utilizes a patent-pending algorithm to dynamically select and integrate PRS models from genome-wide association studies (GWAS), calibrating these models against Galatea's Global Biobank database for accurate risk stratification across diverse ethnic backgrounds. This enables laboratories to combine StrataRisk™ with existing gene panel testing, providing a more comprehensive genomic interpretation.

The platform's key innovation lies in its ability to adjust risk scores based on an individual's "genetic neighborhood," mitigating biases inherent in PRS models predominantly trained on European ancestry populations. StrataRisk™ initially covers eight cardiovascular and metabolic traits, including atrial fibrillation, coronary artery disease, and type 2 diabetes, with plans to expand to hereditary cancer traits. StrataRisk™ aims to provide clinical laboratories with actionable insights, enabling personalized screening recommendations and improved patient care.